Active Ingredient History

  • Now
Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure. Eprosartan is indicated for the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).   NCATS

  • SMILES: CCCCc1ncc(\C=C(/Cc2cccs2)\C(=O)O)n1Cc3ccc(cc3)C(=O)O
  • Mol. Mass: 424.52
  • ALogP: 4.74
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)


$0.2680 - $0.5258
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

2-thiophenepropanoic acid, alpha-((2-butyl-1-((4- carboxyphenyl)methyl)-lh-imidazol-5-yl)methylene)-, (e)- | (e)-2-butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid | (e)-3-[2-n-butyl-1-{(4-carboxyphenyl)methyl}-1h-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid | (e)-alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1h-imidazole-5-yl]methylene}-2-thiopheneproprionic acid | eposartan | eprosartan | éprosartan | eprosartan mesilate | eprosartan mesylate | eprosartanum | sk-108566 | sk&f 108566 | sk&f-108566 | skf-108566 | sk&f-108566j | sk&f-108566-j | teveten


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue